$-0.56 EPS Expected for ACADIA Pharmaceuticals Inc. (ACAD) as of May, 8

April 16, 2018 - By Michele Cranor

During 2017 Q4 the big money sentiment increased to 1.26. That’s change of 0.25, from 2017Q3’s 1.01. 30 investors sold all, 47 reduced holdings as ACADIA Pharmaceuticals Inc. ratio is positive. 65 increased stakes while 32 funds took stakes. Funds hold 117.35 million shares thus 3.35% more from 2017Q3’s 113.55 million shares.
Group Incorporated One Trading Lp owns 133,080 shs for 0.03% of their capital. Great West Life Assurance Can holds 0% or 11,789 shs. Cap Investors holds 0.02% of its capital in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 2.83 million shs. Legal General Group Pcl owns 0% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 50,339 shs. Art Advsrs Ltd Com has 0.08% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 59,605 shs. Bb&T Securities Ltd Limited Liability Company accumulated 12,658 shs. Creative Planning holds 72,314 shs. Millennium Management Limited holds 0% or 86,781 shs. Tocqueville Asset Mgmt Limited Partnership, New York-based fund reported 31,160 shs. Sg Americas Secs Ltd Co owns 63,934 shs. Stanley has 1.96% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 301,105 shs. Manufacturers Life Insurance The reported 4,034 shs. Baker Bros Ltd Partnership reported 7.11% stake. Brown Brothers Harriman & reported 106 shs. Alliancebernstein Ltd Partnership holds 0% or 98,287 shs.

ACADIA Pharmaceuticals Inc. had 3 selling transactions and 1 buy since January 2, 2018. This’s net activity of $3.94 million. The insider Brege Laura sold $751,543. SOLAND DANIEL B had bought 10,000 shs worth $234,910 on Thursday, March 1.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)’s quarterly earnings will be revealed On May, 8., Faxor reports. The EPS diference is $0.16 or 22.22 % up from last years number. Previous year: $-0.72; Analysts forcast: $-0.56. Wall Street now forecasts 1.82 % negative EPS growth despite ACADIA Pharmaceuticals Inc. last quarter’s EPS of $-0.55. On during the last trading session the stock increased $0.08 or 0.42%, reaching $18.98.ACADIA Pharmaceuticals Inc. has volume of 1.46M shares. Since April 16, 2017 ACAD has declined 36.38% and is downtrending. ACAD underperformed by 47.93% the S&P 500.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Ratings Coverage

In total 4 analysts cover ACADIA Pharmaceuticals Inc (NASDAQ:ACAD). “Buy” rating has 4, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 6 are the (NASDAQ:ACAD)’s analyst reports since November 7, 2017 according to StockzIntelligence Inc. On Tuesday, April 10 Needham maintained the shares of ACAD in report with “Buy” rating. On Tuesday, April 10 the company was maintained by Cowen & Co. On Monday, November 13 the company was maintained by Cowen & Co. The company rating was maintained by H.C. Wainwright on Wednesday, November 8. On Tuesday, November 7 the firm has “Buy” rating by Cowen & Co given. On Wednesday, November 8 the stock has “Buy” rating by J.P. Morgan.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders.The company has $2.37 billion market cap. The Company’s lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson's disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimer's disease psychosis.Last it reported negative earnings. The firm has a collaboration with Allergan, Inc. for the development of product candidates related to chronic pain.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.